Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

Abstract

Due to an unexpected increase in serious cardiovascular event in MS patient treated with Linomide, a synthetic immunomodulator, two phase-III multinational relapsing remitting (RR) and secondary progressive (SP) MS trials had to be discontinued. MRI result of 413 patient who participated for at least 3 months were analysed. Patient received placebo, 2.5 or 5 mg Linomide. Scans were performed at pre-enrolment, month 3 and termination. The number and volume of enhancing lesions (ELV), and the number of active scans were evaluated At month 3, the decrease in the number of enhancing lesions in the placebo group was I I1%, compared with 15% in the 2.5 mg group (P=0.027) and 23% in the 5 mg group (P=0.057). Using the percentage of active scans as outcome parameter, the odds ratio for improvement between placebo and 2.5 mg group was 1.62 (P=0.14); between placebo and 5 mg Linomide group 3.58 (P=0.003). At termination, a rebound effect was noted in the 2.5 mg group (P=0.0 1). Analysis of the ELV showed no significant difference between placebo and treatment groups. Although Linomide has unacceptable side effect, it seems to have a modest effect on MS disease activity, as measured by MRI.

Keywords

magnetic resonance imaging multiple sclerosis Linomide

Get full access to this article

View all access options for this article.

References

The IFNB . (1995) Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis . Neurology 45: 1277-1285 .

Stone LA et al. (1997) Characterization of MRI response to the treatment with interferon beta-lb . Neurology 49: 862-869 .

Johnson KP et al. (1995) Copolymer 1 reduces relapse rates and improves disability in relapsing remitting multiple sclerosis . Neurology 45: 1268-1276 .

Mancardi GL et al. (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis . Neurology 50: 1127-1133 .

Bastianello S et al. (1994) A controlled trial of mitoxan-trone in multiple sclerosis: serial MRI evaluation at one year . Con J Neurol Sci 21: 266-270 .

Tian WZ et al. (1998) Linomide (Roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis . Acta Neurol Scand 98: 94-101 .

Karussis D et al. (1993) Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide (quino-line-3-carboxamide) . Proc Natl Acad Sci 90: 6400-6404 .

Karussis D et al. (1993) Inhibition of acute experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide . Ann Neurol 34: 654-660 .

Diab A et al. (1998) Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammator versus anti-inflammatory cytokines . J Neuroimmunol 85: 146-154 .

10.

Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis . Ann Neurology 39: 6-16 .

11.

Barkhof F et al. (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials . J Neurol 244: 76-84 .

12.

Miller DH , Barkhof F , Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis . Brain 116: 1077-1094 .

13.

Karussis DM et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation . Neurology 47: 341-346 .

14.

Andersen O et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis . Neurology 47: 895-900 .

15.

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 83: 1444-1452 .

16.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurology 13: 1227-1231 .

17.

Offenbacher H et al. (1993) Assessment of MRI criteria for a diagnosis of MS . Neurology 43: 905-909 .

18.

Paty DW et al. (1988) MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT . Neurology 38: 180-185 .

19.

Filippi M et al. (1997) Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis . Acta Neurol Scand 95: 331-334 .

20.

Barkhof F et al. (1997) Improving interobserver variation in reporting gadolinium-enhanced MS lesions . Neurol ogy 49: 1682-1688 .

21.

Xiao BG et al. (1998) Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and il-1-beta expression in Lewis rat glial cells . Neurosci Lett 249: 17-20 .